Hepatotoxicity to Risperidone

Rita Trindade André, MD; Joana Pereira Romão, MD; Marta Segadaes Rebelo, MD; Francisca Correia Pais, MD; Ana Monteiro Fernandes, MD; Patrícia Martins Baronet, MD; Manuela Neves Abreu, MD

Prim Care Companion CNS Disord 2024;26(2):23cr03658

Free Access: Please Log In

This content is completely free—but you need to be logged in to read the full article. If you already have an account, please log in below. Otherwise, register for free to unlock instant access.

References (6)

Telles-Correia D, Barbosa A, Cortez-Pinto H, et al. Psychotropic drugs and liver disease: a critical review of pharmacokinetics and liver toxicity. World J Gastrointest Pharmacol Ther. 2017;8(1):26–38. PubMed CrossRef
Iasella CJ, Johnson HJ, Dunn MA. Adverse drug reactions: type A (intrinsic) or type B (idiosyncratic). Clin Liver Dis. 2017;21(1):73–87. PubMed CrossRef
Kaufman G. Adverse drug reactions: classification, susceptibility and reporting. Nurs Stand. 2016;30(50):53–63. PubMed CrossRef
Shehu AI, Ma X, Venkataramanan R. Mechanisms of drug-induced hepatotoxicity. Clin Liver Dis. 2017;21(1):35–54. PubMed CrossRef
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda, Maryland: National Institute of Diabetes and Digestive and Kidney Diseases; 2012. Risperidone. [Updated June 4, 2018].
Khorassani F, Sousonis F, Lopez LV. Risperidone- and paliperidone-induced hepatotoxicity: Case report and review of literature. Am J Health Syst Pharm. 2020;77(19):1578–1584. PubMed CrossRef